Suicidal Ideation clinical trials

Explore recruiting suicidal ideation clinical trials.

Recruiting suicidal ideation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Suicidal Ideation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Nitrous Oxide in Resistant Depression in Elderly Subjects: A Randomized, Double-blind, Comparator Trial

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Traitement des Idées Suicidaires aux urgences par adjonction de Protoxyde d’Azote (PROTORISC pilote)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder (BALSAM-3)

Hungary, Romania, Poland, Sweden, Croatia, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The additive effect of ketamine in combination with electroconvulsive stimulation (ECS) in major depressive disorder (MDD): a translational study

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPEN-LABEL SAFETY STUDY OF A 1-YEAR 20MG DOSE REGIMEN OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER (N24HSWD) IN BLIND INDIVIDUALS WITH NO LIGHT PERCEPTION

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder

Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Suicidal Ideation trials by city

Suicidal Ideation in Toronto Suicidal Ideation in Vancouver Suicidal Ideation in Montreal Suicidal Ideation in Calgary Suicidal Ideation in Edmonton Suicidal Ideation in Ottawa Suicidal Ideation in Winnipeg Suicidal Ideation in Quebec City Suicidal Ideation in Hamilton Suicidal Ideation in Kitchener Suicidal Ideation in London Suicidal Ideation in Halifax Suicidal Ideation in New York Suicidal Ideation in Los Angeles Suicidal Ideation in Chicago Suicidal Ideation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease